Introduction {#S1}
============

Asthma diagnosis in sickle cell disease (SCD) patients is associated with worse prognosis, i.e., increased morbidity and mortality ([@B16]). As stated by Mehari and Klings, one of the difficulties in diagnosing asthma in SCD stems from the overlap of clinical features, which may be solely due to SCD and those of asthma in the non-SCD population ([@B28]). The use of beta~2~-agonists in children with SCD and asthma confounds interpretation of whether asthma or asthma treatment is associated with worse SCD as measured by incident acute chest syndrome (ACS) and vaso-occlusive crisis (VOC). For instance, in the study by Glassberg et al., including 74 SCD children, painful episodes with adequate documentation of respiratory symptoms were more frequently preceded by respiratory symptoms in the group with asthma when compared with those without asthma ([@B15]). One may hypothesize that these respiratory symptoms led to the intensification of bronchodilator intake that may further precipitate VOC. Similarly, in the study by [@B40] more of the children who had an ACS compared to those who did not were taking anti-asthma medication.

Our working hypothesis is that beta~2~-agonists may aggravate SCD via their modulating effect on the autonomic nervous system (ANS). The few studies that have investigated ANS functions in patients with SCD have reported alterations such as decreased parasympathetic activity and sympathetic activity predominance in steady-state condition ([@B35]; [@B32]). Furthermore, ANS dysfunction seems to be a marker of severity in SCD ([@B30]). Beta~2~-agonists may further modify ANS balance. Acute salbutamol administration increases sympathetic activity in both healthy and asthmatic subjects ([@B12]; [@B11]). As a consequence, one may hypothesize that beta~2~-agonists may aggravate ANS dysfunction of SCD that is already characterized by enhanced sympathetic activity when compared to its effect in asthmatic patients who exhibit on the opposite an enhanced parasympathetic activity ([@B14]).

Thus, our objectives were to assess ANS functions based on heart rate variability (HRV) in patients with SCD receiving asthma treatment or not, when compared to asthmatic children without SCD, who were matched for ethnicity since its influences HRV ([@B18]), and to assess the effect of salbutamol administration on ANS in these three groups of children.

Materials and Methods {#S2}
=====================

This cross-sectional case (SCD)--control (non-SCD) study complied with STROBE guidelines.

Patients {#S2.SS1}
--------

Subjects of Sub-Saharan African or Caribbean ethnicity who were 8 to 16 years of age and were referred to the Pulmonary Function Testing Unit for the follow-up of their disease were enrolled between January 2018 and April 2019. Three groups were constituted according to the presence of asthma treatment \[either on-demand (salbutamol) or continuous (inhaled corticosteroid or bronchodilator with inhaled corticosteroid or leukotriene receptor antagonist)\] and SCD: SCD children without asthma treatment, SCD children with asthma treatment, and asthmatic children without SCD. For the latter group, the children had to satisfy the GINA criteria of asthma (diagnosis of asthma made by one of the hospital pediatric pulmonologist plus reversible airflow limitation in the past pulmonary function tests in the unit). Since multiple phenotypes of asthma may exist in SCD (at least asthma-like symptoms and typical asthma), all the patients underwent exhaled nitric oxide (NO), characterizing atopy ([@B26]). SCD children were characterized as previously described, thanks to a database as part of standard patient management, VOC was defined as severe enough to require hospitalization, and ACS was defined as new pulmonary infiltrate with pain, fever, and/or hypoxemia ([@B38]). One physician (HEJ) served as chart abstractor. An additional inclusion criterion for all children receiving anti-asthma treatment was the withdrawal of the beta-agonist before lung function tests (short-acting beta~2~-agonist \>4 h and long-acting beta~2~-agonist \>15 h). The sole exclusion criterion was the failure of the HRV analysis. This study was approved by an Ethics Committee (CPP SUD-EST II, 2017-17-AM1) and the database of collected data was declared to the French regulatory agency (CNIL). The subjects and their parents gave their informed consent. The Assistance Publique--Hôpitaux de Paris (DRCI) was the sponsor of the study (DrepaSympa study-K170302).

Pulmonary Function Tests and HRV Analysis {#S2.SS2}
-----------------------------------------

The children/adolescents underwent functional tests, between 9:30 and 12:30 am (no acute consumption of food or water), in the following order:

1.  ECG recorded connection;

2.  Two static volume measurements using a dilution technique (normal breathing frequency: respiratory rate of 20--25/min): 5 min for each recording. These two measurements allowed the calculation of the static volumes as recommended ([@B41]);

3.  One functional residual capacity (FRC) measurement using a dilution technique with slow-paced breathing recording at six cycles per minute \[5 s of inspiration, 5 s of expiration: 5 min as previously described ([@B13])\] in order to study respiratory sinus arrhythmia (RSA) that is recognized as a physiological mechanism to ensure optimal ventilation-perfusion matching within the lungs ([@B17]);

4.  Exhaled NO measurement at multiple flow rates to calculate alveolar NO concentration (C~alv,NO~) and maximal bronchial NO flux (J'~aw,NO~) as previously described ([@B24]). J'~aw,NO~ has been correlated to both subepithelial eosinophilic infiltration and reticular basement membrane thickness, two asthma characteristics ([@B24]). FENO~0.05~ was also given since the modeling failure of the exhaled NO can be observed ([@B25]);

5.  Baseline spirometry, accordingly to recommendations ([@B29]);

6.  DLCO/DLNO measurement to calculate the membrane diffusion (DM) and capillary blood volume (VC), as recommended ([@B42]) (finite θ NO value), in order to characterize SCD ([@B23]);

7.  Salbutamol administration via a space inhaler (400 μg) ([@B29]);

8.  Spirometry 15 min after salbutamol administration to calculate the bronchodilator response as compared to the baseline value;

9.  ECG recorder withdrawal.

Electrocardiographic recording during the pulmonary function tests was acquired with the Holter recorder SpiderView (ELA Medical, SORIN Group, Clamart, France). Analog data were edited on a SyneScope station and further exported in ASCII files. The files were then processed using the HRV analysis software 1.1 downloaded at^[1](#footnote1){ref-type="fn"}^ and validated by [@B34].

Four 5-min periods over the approximately 1-h recording were selected:

1.  Two baseline measurements during the normal breathing FRC measurements that were averaged;

2.  One slow-paced ventilation recording during the slow-paced breathing measurement;

3.  One recording 10 to 15 min after salbutamol administration (before spirometry). This time point was chosen according to the results of [@B12].

From each 5 min recording time and frequency, the domain HRV variables were calculated. Time-domain variables included the mean sinus heart rate (HR), the standard deviation of the RR intervals (SDNN), the percentage of normal consecutive RR intervals differing by N50 ms (pNN-50) and the root mean of squared successive differences (RMSSD). After fast Fourier transform, the power spectrum indices were calculated as recommended ([@B31]). The spectrum was calculated using Welch's periodogram algorithm with a Hamming window of 256 points, an overlap of 50%, and a precision of 256 points/Hz. The total power (Ptot), very low frequencies (VLF: 0--0.04 Hz), low frequencies (LFa: 0.04--0.15 Hz), and high frequencies (HFa: 0.15--0.40 Hz) were calculated. LFa and HFa were also expressed as normalized values LFnu = 100 \* LFa/(Ptot-VLF) and HFnu = 100 \* HFa/(Ptot-VLF), and the LF/HF ratio was calculated.

In accordance with [@B5], LF/HF = (0.50 parasympathetic + 0.25 sympathetic nerve activity)/(0.90 parasympathetic + 0.10 sympathetic nerve activity). Thus, an increase in the LF/HF ratio cannot be assumed to necessarily reflect a shift to "sympathetic dominance" and a decrease in this index as a shift to "parasympathetic dominance" ([@B5]). Moreover, there is a non-linear interaction between the LF and HF that further complicates the interpretation of this ratio.

The paced ventilation response (effect of RSA) was calculated as Δ (stimulated minus baseline condition) of the normalized HF (HFnu).

Since HR variations *per se* influence HRV responses, frequency data (power spectra) were corrected by division with the corresponding mean R-R interval in seconds ([@B4]), giving LHa~corrected~ and HFa~corrected~.

[@B22] determined that the HRV variables can be classified in three independent factors that were used: oscillatory domain (HFnu, LFnu, LF/HF ratio, and possibly ΔHFnu), amplitude domain (Ptot, HFa, and LFa) and a pulse domain (HR and mean RR). When HR fluctuations mediated by autonomic nerves are observed in HF band (\>0.15 Hz), it is mediated by the cardiac vagus ([@B17]).

All pulmonary function tests and HRV indices were also recorded on a standardized abstraction form.

Statistical Analyses {#S2.SS3}
--------------------

Sample size calculation. We planned to include 30 children in each group of patients based on the number of patients included in the previous studies devoted to the ANS function, involving asthmatic or SCD patients ([@B12]; [@B32]; [@B21]; [@B13]).

The results were expressed as median (25--75th percentiles) since most indices followed not normal distribution (HRV indices for instance). Comparisons between the baseline and stimulated conditions were performed using Wilcoxon signed-rank test. Comparisons of the continuous variables between the three groups of children were performed using the Kruskal--Wallis test, and subsequent intergroup comparisons were performed using the Mann--Whitney *U* test. Categorical variables were compared using the chi-square test. Correlations were evaluated using Pearson's correlation coefficient. A *p* value \<0.05 was deemed significant. No correction for multiple testing was done due to the pathophysiological design of the study ([@B36]). All statistical analyses were performed with StatView 5.0 software (SAS Institute, Cary, NC, United States).

Results {#S3}
=======

The HRV analysis was not obtained for one asthmatic child without SCD, leaving 89 children included. The clinical and functional characteristics of the enrolled patients are described in [Table 1](#T1){ref-type="table"}. SCD children with asthmatic symptoms were characterized by a more severe disease, as evidenced by the increased frequency of VOC and ACS. Among these asthmatic SCD children, six were suffering from typical atopic asthma involving several members of the family, including parents, without SCD. Thus, the typical asthma prevalence in our SCD children was 6/60 (10%, 95% CI: 2--18). Overall, the SCD children were more often treated by a short-acting bronchodilator than asthmatic non-SCD children who received ICS/LABA combination more frequently.

###### 

Clinical characteristics of the 89 enrolled children.

  **Clinical characteristics**     **Non asthmatic SCD *N* = 30**   **Asthmatic SCD *N* = 30**   **Asthma without SCD *N* = 29**   ***P*value**
  -------------------------------- -------------------------------- ---------------------------- --------------------------------- --------------
  Age, years                       12.7 \[10.9; 14.5\]              12.9 \[10.7; 14.0\]          11.4 \[10.1; 12.7\]               0.058
  Sex, female/male                 18/12                            14/16                        18/11                             0.430
  Height, cm                       153 \[142; 162\]                 152 \[144; 163\]             154 \[142; 159\]                  0.878
  Weight, kg                       40.5 \[34.0; 51.0\]              39.5 \[33.0; 49.0\]          42.0 \[38.7; 60.5\]               0.214
  ***Asthma characteristics***                                                                                                     
  Typical asthma, n                0                                6                            29                                ND
  GINA, 0/1/2/3/4                                                   14/10/3/3/0                  17/3/5/3/1                        0.236
  Controlled asthma, n                                              14                           17                                0.438
  SABA, n                                                           18                           7                                 0.002
  ICS, n                                                            1                            1                                 \>0.999
  LTRA, n                                                           0                            1                                 0.492
  ICS/LABA, n                                                       11                           20                                0.019
  ***SCD characteristics***                                                                                                        
  Genotype, SS, SC, Sβ°            22/6/2                           26/3/1                                                         0.435
  Deficit G6PD, n                  1                                1                                                              \>0.999
  VOC^\#^, n patients              22                               27                                                             0.181
  VOC^\#^, n last year             0.0 \[0.0; 0.5\]                 1.0 \[0.0; 2.0\]                                               0.002
  ACS, n patients                  5                                14                                                             0.025
  ACS, total number/child          0.0 \[0.0; 0.0\]                 0.0 \[0.0; 1.0\]                                               0.018
  Cerebral vasculopathy\*, n       7                                12                                                             0.267
  Hydroxyurea                      16                               20                                                             0.429
  Previous transfusion program     7                                7                                                              \>0.999
  Hemoglobin, g/dL                 9.4 \[8.4; 10.5\]                8.5 \[7.8; 9.0\]             NA                                0.054
  Leucocyte count, × 10^+9^/L      7.7 \[6.4; 10.2\]                8.2 \[7.3; 10.3\]            NA                                0.391
  Reticulocyte count, × 10^+9^/L   188 \[148; 270\]                 197 \[147; 308\]             NA                                0.554
  Lactic dehydrogenase, IU/L       491 \[355; 621\]                 511 \[418; 941\]             NA                                0.114

SABA, short-acting beta

2

-agonist; ICS, inhaled corticosteroid; LTRA, leukotriene receptor antagonist; ICS/LABA, combination of low dose of ICS and long-acting beta

2

-agonist. NA denotes Not Available.

\#

Vaso-occlusive crisis requiring hospitalization. \*Cerebral vasculopathy has been defined as high stroke risk as previously done (

Sommet et al., 2016

).

Pulmonary Function Tests ([Table 2](#T2){ref-type="table"} and [Table A1](#A1.T1){ref-type="table"}) {#S3.SS1}
----------------------------------------------------------------------------------------------------

Asthmatic subjects, with or without SCD, depicted a mild baseline airflow limitation (reduced FEV~1~/FVC *z*-score) and a higher bronchodilator response than non-asthmatic SCD children. Increased exhaled NO values were observed in non-SCD asthmatic children when compared to SCD children, whether or not they were suffering from asthma. Bronchodilator response positively correlated with both J'~aw,NO~ (*R* = + 0.26, *p* = 0.019, *n* = 83) and FENO~0.05~ (*R* = + 0.22, *p* = 0.043, *n* = 89). The median DLCO values% predicted were elevated in the three groups of children, and even significantly higher in asthmatic non-SCD children as compared to SCD children (see [Table A1](#A1.T1){ref-type="table"}). The VC/VA values of the SCD groups were higher than that of asthmatic non-SCD children.

###### 

Lung functional characteristics of the 89 enrolled children.

  **Functional characteristics**           **Non asthmatic SCD *N* = 30 (group 1)**   **Asthmatic SCD *N* = 30 (group 2)**   **Asthma without SCD *N* = 29 (group 3)**   ***P* Value**   **Intergroup Comparisons^\#^**
  ---------------------------------------- ------------------------------------------ -------------------------------------- ------------------------------------------- --------------- --------------------------------
  ***Baseline lung function***                                                                                                                                                           
  FEV~1;~ L                                2.17 \[1.65; 2.64\]                        1.97 \[1.55; 2.38\]                    2.06 \[1.83; 2.50\]                         0.383           
  FEV~1~, % predicted                      101 \[85; 106\]                            88 \[78; 97\]                          100 \[92; 105\]                             0.003           2 \< 1 = 3
  FEV~1~ z-score                           +0.07 \[−1.17; +0.46\]                     −0.89 \[−1.65; −0.26\]                 +0.00 \[−0.60; +0.50\]                      0.003           2 \< 1 = 3
  FVC, L                                   2.34 \[1.94; 2.93\]                        2.28 \[1.87; 2.75\]                    2.49 \[2.22; 3.01\]                         0.334           
  FVC, % predicted                         99 \[86; 105\]                             95 \[84; 102\]                         105 \[99; 118\]                             0.001           1 = 2 \< 3
  FVC, z-score                             −0.08 \[−1.15; +0.41\]                     −0.43 \[−1.24; +0.16\]                 +0.40 \[−0.05; +1.44\]                      0.001           1 = 2 \< 3
  FEV~1~/FVC                               0.89 \[0.86; 0.90\]                        0.84 \[0.80; 0.86\]                    0.83 \[0.79; 0.86\]                         0.001           1 \> 2 = 3
  FEV~1~/FVC, z-score                      −0.00 \[−0.44; +0.53\]                     −0.71 \[−1.25; −0.29\]                 −0.99 \[−1.57; −0.25\]                      0.001           1 \> 2 = 3
  ***Exhaled NO\****                                                                                                                                                                     
  C~alv,NO~, ppb (*n* = 83)                3.2 \[2.3; 5.3\]                           3.4 \[1.6; 5.4\]                       7.1 \[3.3; 11.4\]                           0.003           1 = 2 \< 3
  J'~aw~,~N0~, nL/min (*n* = 83)           22 \[16; 35\]                              16 \[9; 46\]                           57 \[24; 104\]                              0.001           1 = 2 \< 3
  [FENO]{.smallcaps}~005~,Ppb (*n* = 89)   10.3 \[6.9; 15.0\]                         8.0 \[5.4; 18.8\]                      20.8 \[13.8; 34.5\]                         0.001           1 = 2 \< 3
  ***Post-bronchodilator***                                                                                                                                                              
  FEV~1~ L                                 2.18 \[1.73; 2.69\]                        2.07 \[1.70; 2.45\]                    2.19 \[1.92; 2.64\]                         0.425           
  FEV~1~, % predicted                      104 \[89; 109\]                            94 \[87; 103\]                         108 \[102; 117\]                            0.001           1 = 2 \< 3
  FEV~1~, z-score                          +0.30 \[−0.86; +0.64\]                     −0.49 \[−1.03; +0.24\]                 +0.63 \[+0.15; +1.33\]                      0.001           1 = 2 \< 3
  Bronchodilator response, %               +3 \[−1; +5\]                              +4 \[+2; +9\]                          +7 \[+3; +12\]                              0.004           1 \< 2 = 3
  FVC, L                                   2.40 \[1.97; 2.85\]                        2.29 \[1.98; 2.74\]                    2.51 \[2.27; 3.15\]                         0.277           
  FVC, % predicted                         100 \[86; 107\]                            96 \[86; 104\]                         110 \[102; 117\]                            0.001           1 = 2 \< 3
  FVC, z-score                             +0.02 \[−1.09; +0.51\]                     −0.34 \[−1.11; +0.32\]                 +0.77 \[+0.15; +1.33\]                      0.001           1 = 2 \< 3
  FEV~1~/FVC,                              0.91 \[0.88; 0.92\]                        0.88 \[0.84; 0.91\]                    0.86 \[0.83; 0.90\]                         0.005           1 \> 2 = 3
  FEV~1~/FVC, z-score                      +0.47 \[−0.25; +0.73\]                     +0.05 \[−0.52; +0.36\]                 −0.36 \[−0.74; +0.16\]                      0.008           1 \> 2 = 3

\*Alveolar NO concentration (C

alv,NO

) and maximum NO flux from bronchial tree (J'

aw,NO

) were not obtained in six subjects in whom the linearity of the relationship between the exhaled NO flux and expiratory rate was not observed (failure of the model) (

Mahut et al., 2006

).

\#

Post hoc

two-group comparisons were performed using the Mann--Whitney

U

test or the chi-square test, as appropriate (see section "Materials and Methods"). For additional lung function tests, see

Table A1

.

Baseline HRV Variability ([Table 3](#T3){ref-type="table"}) {#S3.SS2}
-----------------------------------------------------------

Sickle cell disease children were characterized by a reduced HRV (SDNN, Ptot for instance) that was related to the reduced values of both HFa and LFa of similar degrees since the HFnu and LFnu and LF/HF ratio were similar. Thus, only the amplitude domain was decreased. HFnu, and logically LFnu, significantly correlated with the FEV~1~ *z*-score (*R* = 0.22, *p* = 0.034, *R* = −0.23, *p* = 0.030; respectively). No other significant correlation was observed between the HRV parameters and pulmonary function test parameters, which were evaluated since airflow limitation could have been related to enhanced parasympathetic tone.

###### 

Baseline heart rate variability characteristics of the 89 enrolled children.

  **Functional characteristics**   **Non asthmatic SCD**   **Asthmatic SCD**     **Asthma without SCD**   ***P* value**   **Intergroup**
  -------------------------------- ----------------------- --------------------- ------------------------ --------------- ----------------
  ***Pulse domain***                                                                                                      
  RR, ms                           680 \[619; 714\]        682 \[649; 736\]      685 \[639; 747\]         0.696           
  HR, beats/min                    89 \[85; 97\]           89 \[82; 93\]         88 \[82; 95\]            0.755           
  ***Amplitude domain***                                                                                                  
  pNN50, %                         26 \[13; 41\]           18 \[7; 33\]          29 \[15; 39\]            0.118           
  SDNN, ms                         60 \[48; 74\]           54 \[40; 83\]         75 \[61; 97\]            0.006           1 = 2 \< 3
  RMSSD, ms                        45 \[32; 63\]           40 \[27; 66\]         53 \[37; 75\]            0.128           
  Ptot, ms^2^                      3454 \[1824; 5017\]     2264 \[1187; 4947\]   5396 \[3246; 7397\]      0.007           1 = 2 \< 3
  VLF, ms^2^                       1006 \[592; 2209\]      779 \[387; 1588\]     1686 \[1124; 3146\]      0.012           1 = 2 \< 3
  LFa, ms^2^                       857 \[449; 1414\]       593 \[366; 1430\]     1318 \[669; 1925\]       0.028           1 = 2 \< 3
  HFa, ms^2^                       924 \[446; 1453\]       661 \[327; 1145\]     1414 \[692; 2288\]       0.010           1 = 2 \< 3
  ***Oscillatory domain***                                                                                                
  LFnu, %                          44 \[35; 50\]           48 \[35; 55\]         45 \[30; 55\]            0.760           
  HFnu, %                          39 \[31; 50\]           41 \[30; 48\]         41 \[32; 51\]            0.672           
  LF/HF ratio                      1.19 \[0.94; 1.64\]     1.16 \[0.83; 1.91\]   1.19 \[0.61; 1.80\]      0.686           

HRV Variability in Stimulated Conditions (Paced Ventilation, Salbutamol) {#S3.SS3}
------------------------------------------------------------------------

In the whole population (*n* = 89), as compared with the baseline, paced ventilation was associated with a significant increase in Ptot (6418 ms^2^ \[3384; 10294\] versus 3497 \[1941; 6422\], *p* \< 0.001) that was related to an increase in LFa (3743 ms^2^ \[1401; 7460\] versus 875 \[456; 1689\], *p* \< 0.001). Both HFa (*p* = 0.088) and HR were not modified (88 beats/min \[83; 95\] versus 89 \[80; 97\], *n* = 89; *p* = 0.359). The LH/HF ratio significantly increased with paced ventilation (5.5 \[1.5; 11.3\] versus 1.17 \[0.79; 1.80\], *p* \< 0.001). Thus, both amplitude and oscillatory domains were modified. Additionally, as compared to baseline, HFa under paced ventilation significantly decreased in non-SCD asthmatic children (*p* \< 0.001, *n* = 29) while it did not decrease in SCD children (*p* = 0.497, *n* = 60), explaining the trend evidenced in the whole population (*n* = 89).

The response to paced ventilation differed among the three groups and is described in [Figure 1](#F1){ref-type="fig"}; asthmatic non-SCD children were characterized by lower HFnu during paced ventilation when compared to SCD children while their HFa values were similar. Asthmatic non-SCD children exhibited a higher decrease in ΔHFnu. This decrease correlated with VC/VA ([Figure 2](#F2){ref-type="fig"}). HFnu during paced ventilation also correlated with VC/VA (*R* = 0.373, *p* \< 0.001).

![Response to paced ventilation (respiratory sinus arrhythmia evaluation). The upper panel is the HFa (raw values of HF), the middle panel is the normalized HF (Hfnu), and the lower panel is the ΔHFnu (stimulated minus baseline condition). *p* values are those of the Kruskal--Wallis test between the three groups. The Mann--Whitney *U* test further demonstrated that the two SCD groups differed from the asthmatic non-SCD group in the middle and lower panels (data not shown). Box and whisker plots show median, 25 and 75th percentiles, and 10 and 90th percentiles.](fphys-11-00031-g001){#F1}

![Relationship between the effect of paced ventilation and VC/VA. A significant correlation was evidenced between VC/VA and ΔHFnu: *R* = 0.406, *p* = 0.0002. Black circles are SDC children while open circles are asthmatic non-SCD children.](fphys-11-00031-g002){#F2}

In the whole population (*n* = 89), as compared with baseline, salbutamol administration was associated with a significant increase in HR (95 beats/min \[92; 102\] versus 88 \[83; 95\], *p* \< 0.001), which was even higher in SCD children when compared to asthmatic non-SCD children: 97 beats/min \[93; 105\] versus 94 \[87; 95\] (*p* = 0.024). Ptot significantly decreased after salbutamol when compared to the baseline condition (2754 ms^2^ \[1583; 4882\] versus 3497 \[1941; 6422\], *p* = 0.014), which was mainly related to a significant decrease in HFa (503 ms^2^ \[233; 937\] versus 943 \[435; 1710\], *p* \< 0.001). This decrease remained significant even correcting for the HR modification: HFa~corrected~, salbutamol = 831 ms^2^/s \[370; 1392\] versus baseline = 1410 ms^2^/s \[697; 2236\], *p* \< 0.001. Salbutamol administration was associated with a significant increase in the LF/HF ratio (1.57 \[0.98; 2.58\] versus 1.17 \[0.79; 1.80\], *p* = 0.005). Thus, the three domains of HRV were modified.

The response to salbutamol also differed between the three groups since asthmatic non-SCD children depicted a lower LF/HF ratio when compared to SCD children ([Figure 3](#F3){ref-type="fig"}) and since they also depicted a higher HFnu (36% \[29; 43\]) versus the two SCD groups (non-asthmatic: 29% \[20; 42\] and asthmatic: 29% \[19; 40\]; *p* = 0.046).

![Response to salbutamol stimulation. Sympathetic stimulation was obtained after 400 μg of salbutamol administration (10 min after inhalation). The six SCD patients with typical asthma are individualized in the SCD asthma group as circles on the left side of the group with the black contour line. The *p* value is that of the Kruskal--Wallis test between the three groups. The Mann--Whitney *U* tests further demonstrated that the two SCD groups differed from the asthmatic non-SCD group (data not shown). The box and whisker plots show median, 25 and 75th percentiles, and 10 and 90th percentiles.](fphys-11-00031-g003){#F3}

HRV Variability in Subgroups of SCD Children {#S3.SS4}
--------------------------------------------

Overall, there was no difference among all the HRV parameters between the two groups of SCD children. It has previously been emphasized that ANS dysfunction could be a marker of SCD severity; we therefore assessed ANS functions in SCD children with (*n* = 49) and without (*n* = 11) hospitalization for VOC, demonstrating that HFnu and ΔHFnu under paced ventilation were significantly different in children without any hospitalization for VOC (15% \[7; 24\] and −23% \[−32; −8\], respectively) when compared to those with (39% \[19; 45\] and −6% \[−24; +6\], respectively; *p* = 0.011 and *p* = 0.030). As previously done by [@B21], we compared SCD children with and without history of a ACS showing that children who already had an ACS, when compared to those without a previous ACS, were characterized by lower values of both baseline HFa (404 ms^2^ \[228; 895\] versus 931 ms^2^ \[601; 1345\], respectively; *p* = 0.046) and pNN50 (13% \[6;25\] versus 28% \[12; 41\], respectively; *p* = 0.029), the latter being correlated with the number of ACS events (*R* = −0.29, *p* = 0.023).

Genotype is also a marker of severity; we compared HRV indices in severe genotypes (SS and β°, *n* = 51) as compared to a less severe genotype (SC, *n* = 9), demonstrating the absence of difference for any index.

Discussion {#S4}
==========

Our cross-sectional pathophysiological study demonstrates that SCD children are characterized by a decreased HRV in the resting condition that further decreased upon salbutamol administration. Our working hypothesis was that either asthma diagnosis or bronchodilator treatment might aggravate SCD via their modulating effect on ANS. Our results argue for the latter hypothesis since ANS functions were similar in the two groups of SCD children while that with asthma had more vaso-occlusive events. As a consequence, these events may have been precipitated by salbutamol administration, which warrants further clinical demonstration.

Representativeness of the Three Groups {#S4.SS1}
--------------------------------------

Sickle cell disease children with asthma-like symptoms were characterized by some degree of airflow limitation and bronchodilator response when compared to non-asthmatic SCD children, explaining the prescription of asthma treatment that was mainly SABA for a cough or wheezing episodes. SCD children with asthma depicted a more severe disease according to the incidence of VOC and ACS. SCD patients with a diagnosis of asthma did not exhibit increased exhaled NO values, as previously demonstrated ([@B10]; [@B9]). Asthmatic non-SCD children were characterized by an increase in exhaled NO that explained the relationship between bronchodilator response and exhaled NO, as previously evidenced ([@B27]). They also demonstrated an increased DLCO% predicted as previously evidenced in asthmatic patients ([@B39]), while their VC/VA values were lower than those of SCD children, as expected ([@B10]). Asthmatic SCD and asthmatic non-SCD children were clearly differentiated from a pathophysiological point of view, even if a restricted number of SCD children had typical asthma. Overall, despite the small sample of patients, every single group may seem representative of each disease state previously described.

Representativeness of HRV {#S4.SS2}
-------------------------

The interpretation of HRV results is a challenging issue ([@B5]; [@B22]). The first issue deals with the results of stimulated conditions when compared to the baseline condition. Stimulation by paced ventilation induced an increase in the HRV (increase in Ptot) that was related to LFa that resulted in an increase in the LF/HF ratio as previously evidenced in asthmatic and control subjects using a similar breathing pattern ([@B2]; [@B13]). Stimulation by salbutamol administration induced an increase in HR, a decrease in Ptot and HFa, and an increase in LF/HF ratio as previously demonstrated in asthmatic children ([@B19]). As a consequence, our stimulated conditions reproduced the findings of previous authors in asthmatic patients. Furthermore, the correlation between FEV~1~ and both LHnu and HFnu has previously been evidenced in both asthmatic and healthy subjects ([@B13]).

### HRV Interpretation {#S4.SS2.SSS1}

In the baseline condition, SCD children were characterized by a frank reduction in HRV with a similar LF/HF ratio than asthmatic non-SCD children, suggesting an autonomic dysfunction in the form of impaired parasympathetic tone and sympathetic overactivity, demonstrated by previous authors using continuous non-invasive blood pressure and peripheral vascular resistance ([@B6]). Interestingly, [@B6] recently demonstrated that low parasympathetic activity at baseline dramatically increased the probability of belonging to a peripheral vasoconstriction endotype in SCD subjects, even after adjusting for hemoglobin level, suggesting a characteristic ANS dysfunction that is independent of anemia ([@B7]).

Paced ventilation induced an increase in Ptot, LFa, and LF/HF ratio that was expected ([@B17]). Whereas HFa decreased in asthmatic children as usually evidenced in healthy subjects, this decrease was not observed in SCD children. RSA ensures optimal ventilation-perfusion matching within the lungs ([@B17]), which is defective in SCD patients ([@B33]) who are characterized by an increased lung capillary blood volume ([@B10]). We show that the increased VC/VA of SCD children is associated with lesser effect of RSA; thus, an already recruited vascular bed is associated with the loss of RSA effect, which may participate to the mild degree of hypoxemia in SCD patients ([@B10]). These effects of respiratory parameters on the RSA operate independently of the level of cardiac vagal activity ([@B17]). When respiration frequency is \<0.15 Hz, RSA becomes a part of the LF component, as observed in our study, and the association between HF component and cardiac vagal function is lost ([@B17]). Asthmatic non-SCD children were characterized by a more frank decrease in HF as compared to SCD children. Even though the ANS cannot transfer HRV \>0.15 Hz, it may restrict the magnitude of cardiac vagal modulations of heart rate ([@B17]), which may explain the observed effects. Thus, the different effects of paced ventilation in SCD and non-SCD children may be explained by the increased sympathetic modulation in SCD.

More importantly for our study question, the two groups of SCD children were similar, suggesting that the diagnosis of asthma *per se* did not modify ANS functions. Since the SCD children with asthma-like symptoms were characterized by an increased prevalence of both VOC and ACS, one may, therefore, hypothesize that asthma treatment could have been involved in vaso-occlusive events. Along this line, salbutamol administration in SCD children further modified the ANS balance toward a deregulated profile similar to that observed during VOC. [@B8] showed that HFa decreased during VOC compared to the steady state, suggesting parasympathetic withdrawal that certainly caused the dominance of the sympathetic activity over the parasympathetic activity, as reflected by the increase in LF/HF during VOC. Finally, we show that markers of SCD severity (hospitalization for VOC or occurrence of ACS) were associated with ANS modifications that may suggest parasympathetic withdrawal, as previously evidenced for ACS ([@B21]).

The baseline modifications of HRV could be related to beta-adrenergic stimulation, which has been shown to result in a significant decrease in time domain measures of HRV ([@B1]). Epinephrine has also been shown to promote red blood cell adhesion and vaso-occlusion in SCD ([@B43]). Moreover, genetic variation in the beta-1 ([@B3]) and beta-2 ([@B20]) adrenergic receptors has been shown to influence pulmonary hypertension prevalence and chronic pain severity in SCD. Thus, sympathetic nervous system inhibition may be a therapeutic approach in SCD.

For years, the scientific community has worked under the paradigm that the asthma exacerbation, not the treatment, is the likely trigger for VOC. This made sense because asthma exacerbation limits airflow and oxygenation that would worsen sickling. Nevertheless, [@B37] have shown that desaturation did not induce change in microvascular perfusion in SCD patients. Therefore, other mechanisms had to be found to justify this high risk of VOC, which was the subject of this study.

Limitations of the Study {#S4.SS3}
------------------------

Our study has limitations due to its design. We did not include healthy control children. Nevertheless, our objective was to assess whether the pathophysiology of asthmatic SCD was similar to that of asthmatic without SCD since one may have initially hypothesized that asthmatic SCD would depict similar findings than asthmatic without SCD when compared to SCD children without asthma, justifying their severity and our design. Furthermore, ANS comparisons have previously been obtained between both asthmatic and healthy subjects and between SCD patients and healthy subjects, showing that baseline HRV is similar in asthmatic patients and healthy subjects ([@B30]; [@B13]). Importantly, our data have been obtained in baseline stable condition, which is probably not representative of the setting leading to salbutamol administration, i.e., asthma-like symptoms indicating SCD worsening. Finally, our results do not demonstrate the causality relationship between salbutamol administration and increased vaso-occlusive events in SCD children, which remains to be further evaluated in a prospective design.

In conclusion, these data suggest that SCD children have altered autonomic activity that is worsened by salbutamol administration.
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###### 

Static lung volumes and lung diffusion of the 89 enrolled children.

  **Functional characteristics**                                     **Non asthmatic SCD**   **Asthmatic SCD**     **Asthma without SCD**   **P value**   **Intergroup**
  ------------------------------------------------------------------ ----------------------- --------------------- ------------------------ ------------- ----------------
  ***Baseline lung function***                                                                                                                            
  TLC, L                                                             3.14 \[2.49; 3.72\]     3.05 \[2.67; 3.55\]   3.32 \[2.56; 3.79\]      0.899         
  TLC, % predicted                                                   100 \[90; 107\]         95 \[89; 102\]        101 \[90; 108\]          0.322         
  FRC, L                                                             1.38 \[1.10; 1.78\]     1.46 \[1.19; 1.70\]   1.45 \[1.07; 1.82\]      0.982         
  FRC, % predicted                                                   95 \[82; 114\]          95 \[83; 111\]        97 \[85; 115\]           0.906         
  RV, L                                                              0.87 \[0.66; 1.17\]     0.89 \[0.82; 1.15\]   0.81 \[0.56; 1.01\]      0.207         
  RV, % predicted                                                    107 \[83; 134\]         106 \[90; 127\]       90 \[70; 116\]           0.145         
  VA, L                                                              3.14 \[2.77; 3.82\]     3.06 \[2.64; 3.76\]   3.32 \[2.92; 4.07\]      0.342         
  VA, % predicted                                                    99 \[88; 108\]          101 \[84; 111\]       109 \[102; 123\]         0.013         1 = 2 \< 3
  DLCO, mL/mmHg/min                                                  18.3 \[16.6; 22.9\]     18.0 \[14.5; 21.7\]   22.0 \[19.1; 24.7\]      0.010         1 = 2 \< 3
  DLCO, % predicted                                                  112 \[98; 138\]         112 \[90; 124\]       141 \[122; 151\]         0.001         1 = 2 \< 3
  [DM]{.smallcaps}co/[VA]{.smallcaps}, mL/mmHg/min/[L]{.smallcaps}   19.6 \[17.5; 22.1\]     18.2 \[16.6; 19.3\]   24.8 \[21.7; 28.7\]      0.001         1 = 2 \< 3
  VC/VA, mL/L                                                        22.0 \[20.0; 27.8\]     26.5 \[22.2; 29.4\]   17.1 \[13.3; 20.9\]      0.001         1 = 2 \> 3

VA denotes alveolar volume.

\#

Post hoc

two-group comparisons were performed using the Mann--Whitney

U

test or the chi-square test, as appropriate (see section "Materials and Methods").
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